KAYE RANDALL (CMO) received a stock award from LONGBOARD PHARMACEUTICALS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/9/2024ACC: 0001209191-24-003027
Officer· CMO
Since Mar 2022
+125.48K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
125.48K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+17.92K
Price / share
—
Trade value
—
% of position
New position
2/8/2024
0.00→17.92K
Total
Net shares
+17.92K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/8/2024 | A · Award | +17.92K | — | — | New position | 0.00 | 17.92K |
| Total | +17.92K | $0.00 | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Voting common stock
107.56K shares
Shares
+107.56K
Strike price
19.32
Held after
107.56K
Exercisable
—
2/8/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Voting common stock107.56K shares | 2/8/2024 | A · Award | +107.56K | 19.32 | — | 107.56K |